Peter Heerma, Chief Commercial Officer at Travere Therapeutics, Inc. (TVTX), sold 1,125 shares at $27.40 ($31K) on 2022-01-31, disclosed to the SEC on 2022-02-02.
Scheduled sale ($31k) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| TVTX | SELL | 2026-04-15 | $303K | — | Filing → |
| TVTX | SELL | 2026-02-03 | $235K | — | Filing → |
| TVTX | SELL | 2025-12-29 | $199K | — | Filing → |